相关实验视频

Updated: Jun 29, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

综合基因组和蛋白质组分析确定PYGL是清细胞脏细胞癌的新型实验治疗标

Mingyong Li¹, Guoqiang Zhu¹, Yiqi Liu²

¹The First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.

|March 28, 2024

概括

研究人员确定PYGL是克服清细胞脏细胞癌 (ccRCC) 抗苏尼替尼的新目标. 向PYGL可能会恢复药物敏感性,并改善ccRCC患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

苏尼提尼布是转移性清细胞细胞癌 (ccRCC) 的一线治疗方法.
获得药物耐药性限制了大多数ccRCC患者中sunitinib的长期疗效.
需要新的治疗点来克服ccRCC中sunitinib的耐药性.

研究的目的:

确定ccRCC的新型治疗点.
调查PYGL在ccRCC进展和逊尼提尼布耐药性中的作用.
探索克服ccRCC中苏尼提尼布耐药性的策略.

主要方法:

进行了综合的基因组和蛋白质组分析.
在ccRCC细胞系中使用了CP-91149的PYGL淘汰和向.
进行了染色体免疫沉试验,以确定调节因素.

主要成果:

在ccRCC中,PYGL被确定为一种新的治疗点.
通过PYGL的淘汰,抑制了ccRCC细胞的增殖,入侵和瘤发生.
在抗苏尼替尼的ccRCC细胞中,PYGL的表达被上调,并且针对PYGL恢复了敏感性.
低氧诱导因子1α被确定为PYGL上调调节的诱导因子.

结论:

PYGL是一种有前途的诊断生物标志物和ccRCC的治疗点.
向PYGL提供了一种潜在的策略,以克服ccRCC中苏尼替尼抗性.
结合基因组和蛋白质组方法可以确定新的治疗策略.

关键词:

皮格尔 (PYGL) 是一个人.电阻电阻电阻电阻电阻电阻苏尼蒂尼布 (sunitinib) 是一种药物.目标疗法目标疗法 ccRCCCC 在线观看

更多相关视频

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...